Numeta G13%E marketing suspended in the EU
An EU medicines regulatory committee has endorsed recommendation to suspend the marketing authorization of Numeta G13%E (emulsion for infusion), from Baxter, because of the risk of Hypermagnesaemia. Numeta G13%E, which is given into a vein to premature babies to provide nutritional support, will remain suspended until a re-formulated preparation is made available.
For Numeta G16%E, used in full-term newborns and children up to 2 years, they concluded that updating the product information and a further study, are sufficient to ensure the safe use of this product. The decision will now be implemented directly in all EU Member States.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins